Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Richard Greenberg

Email
Center AffiliationsCancer Biology

Publications (119) (print view)

no pagination
Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, Horwitz EM, Sobczak ML, Chen DY, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG, Smaldone MC. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017 Jul 25;.
Cahn DB, Handorf E, Ristau BT, Geynisman DM, Simhan J, Kutikov A, Greenberg RE, Viterbo R, Chen DY, Uzzo RG, Smaldone MC. Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urol Oncol. 2017 Aug 10;.
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RA, Reed A, Turner SA, de Abreu FB, Gallagher TL, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase Ii Trial of Dovitinib in Bcg-Unresponsive Urothelial Carcinoma with Fgfr3 Mutations or over-Expression: Hoosier Cancer Research Network Trial Hcrn 12-157. Clin Cancer Res. 2017 Jun 15;23(12):3003-11.   PMCID: PMC5462889
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu ZY, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clinical Cancer Research. 2017 Jun;23(12):3003-11.
Ito T, Derweesh IH, Ginzburg S, Abbosh PH, Raheem OA, Mirheydar H, Hamilton Z, Chen DY, Smaldone MC, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG. Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. J Urol. 2017 Jan;197(1):31-6.
Jung K, Ghatalia P, Litwin S, Horwitz EM, Uzzo RG, Greenberg RE, Viterbo R, Geynisman DM, Kutikov A, Plimack ER, Smaldone MC, Wong YN, Bilusic M. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer. 2017 Sep 30;15(3):e337-e343.
McIntosh AG, Li T, Ito T, Mannion J, Dziemianowicz M, Waingankar N, Haseebuddin M, Chen DY, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG, Smaldone MC, Abbosh PH. WBC Associates with Readmission Following Cystectomy. Bladder cancer (Amsterdam, Netherlands). 2017 Apr 27;3(2):95-103.   PMCID: PMC5409152
Shaikh T, Li T, Handorf EA, Johnson ME, Wang LS, Hallman MA, Greenberg RE, Price RA, Uzzo RG, Ma C, Chen D, Geynisman DM, Pollack A, Horwitz EM. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):722-31.   PMCID: PMC5331910
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213-24.
Ito T, Pei J, Dulaimi E, Menges C, Abbosh PH, Smaldone MC, Chen DY, Greenberg RE, Kutikov A, Viterbo R, Uzzo RG, Testa JR. Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features. J Urol. 2016 Apr;195(4P1):852-8.   PMCID: PMC4871784
Johnson ME, Zaorsky NG, Martin JM, Ruth K, Greenberg RE, Uzzo RG, Hayes SB, Smaldone MC, Kutikov A, Viterbo R, Chen DY, Hallman MA, Sobczak ML, Horwitz EM. Patient reported outcomes among treatment modalities for prostate cancer. The Canadian journal of urology. 2016 Dec;23(6):8535-45.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2016 Dec;68(6):959-67.
Shaikh T, Ruth K, Devarajan K, Zaorsky NG, Hallman MA, Sobczak ML, Chen D, Uzzo R, Smaldone MC, Kutikov A, Greenberg RE, Viterbo R, Pollack A, Horwitz EM. Dosimetric and Clinical Predictors of Long-Term Toxicity in Patients Undergoing Hypofractionated Prostate Radiation Therapy: Results From a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2):S123.
Shaikh T, Wang L, Ruth K, Hallman M, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2016 Jan 29;15(2):156-62.   PMCID: PMC4789160
Ginzburg S, Uzzo R, Walton J, Miller C, Kurz D, Li T, Handorf E, Gor R, Corcoran A, Viterbo R, Chen DY, Greenberg RE, Smaldone MC, Kutikov A. Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy. Urology. 2015 Jul 18;86(2):300-6.
Ito T, Abbosh PH, Mehrazin R, Tomaszewski JJ, Li T, Ginzburg S, Canter DJ, Greenberg RE, Viterbo R, Chen DY, Kutikov A, Smaldone MC, Uzzo RG. Surgical apgar score predicts an increased risk of major complications and death after renal mass excision. Journal of Urology. 2015 Jan;193(6):1918-22.
Martin JM, Li T, Johnson ME, Murphy CT, Howald AG, Smaldone MC, Kutikov A, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Horwitz EM. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. J Natl Compr Canc Netw. 2015 May;13(5):525-30.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Shaikh T, Zaorsky NG, Ruth K, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy. 2015 Jan;14(3):316-21.   PMCID: 4424094
Ginzburg S, Uzzo R, Al-Saleem T, Dulaimi E, Walton J, Corcoran A, Plimack E, Mehrazin R, Tomaszewski J, Viterbo R, Chen DY, Greenberg R, Smaldone M, Kutikov A. Coexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal Biopsy. Journal of Urology. 2014 Feb;191(2):296-300.   PMCID: PMC4083459
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Richard Greenberg Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Wednesday, September 06, 2017